Showing posts with label anca vasculitis. Show all posts
Showing posts with label anca vasculitis. Show all posts

Wednesday, December 22, 2021

KDIGO 2021- ANCA vasculitis management

 Check out the latest update in 2021 of treatment of ANCA vasculitis at KDIGO

1. Kidney biopsy is highly recommended in most cases

2. For induction- they recommend that steroids in combination with cyclophosphamide or rituximab be used for new onset AAV. 

3. For patients with GFR that is declining of crt >4.0mg/dl, there is limited data for rituximab based treatment. The combination of cyclo+ ritux can be used in that setting - RITUXIVAS protocol.
 
    4. When to do cytoxan vs rituxan?



5. Reduced dose steroids have shown similar results as high dose steroids( PEXIVAS trial)

6. Dosing for Rituxan and cyclophosphamide


7. Consider plasma exchange with crt >5.7 requiring dialysis or with rapid rise in crt and diffuse alveolar hemorrhage with hypoxemia or overlap syndrome with Anti GBM

8. Maintenance therapy










Wednesday, April 14, 2021

In the NEWs: Hydralazine and the Kidney

Hydralazine- you can love or hate as a nephrologist. Hydralazine is used a lot for both inpatient and outpatient setting my several internists, cardiologists and nephrologists for management of blood pressure. In clinical practice, many times we have noticed vasculitis from hydralazine : both of the lupus or the ANCA kind. Drug induced kidney diseases are important to keep in mind when the clinical picture doesn't make any sense. 

See this exhaustive table from Izzedine and Ng in the recent Kidney News issue on drug induced glomerular diseases. 

A recent study in KI just focused on hydralazine induced ANCA vasculitis and looked at 80 patients.
As suspected, the clinical clues are: many have low complements, +ANCA( both p and c in some cases- 40%), ANA and anti histone positive and even dsDNA positive. When you see several auto antibodies come back positive- think drug induced. Treatment is cessation of the agent and treat like regular vasculitis. 



Check out an old detective nephron from 2013 on this topic.

Thursday, March 13, 2014

TOPIC DISCUSSION: ANCA negative pauci immune vasculitis- what is it?

Approximately 10% of systemic vasculitis patients test negative for ANCA( PR3 or MPO). This group has been studied only infrequently.  It appears that evidence suggests that ANCA negative disease is more renal limited and more severe to the kidney. Some data suggesting that anti endothelial antibodies might be associated with ANCA negative vasculitis.
 Hedger et al. investigated over 30 patients with ANCA-negative rapidly progressive glomerulonepritis and found that they had fewer respiratory findings compared to ANCA positive patients. Eisenberger et al. have identified 20 cases with ANCA negative vasculitis. The renal histology revealed a high percentage of active glomerular lesions (50%), mainly cellular crescents, whereas only 28% of them had glomerular necrosis. Chronic tissue damage with glomerulosclerosis (21%) and diffuse interstitial fibrosis (40%) were already present at diagnosis, more prominent than in historical ANCA positive patients.  Age over 65 was found to be predictor of mortality in this study.
In another study, they found that the level of urinary protein and the prevalence of nephrotic syndrome were significantly higher in ANCA-negative patients than that in ANCA-positive patients. The renal pathology was more severe in ANCA negative groups and the renal survival was poorer as per prior studies.  Treatment has been focused on using combo therapy of either cytoxan+steroids or MMF+steroids.



Thursday, February 20, 2014

Complement system in ANCA vasculitis

          Classically associated with a pauci immune RPGN, ANCA disease has traditionally been not associated with complement activation. Recent data in JASN 2014 from the UNC group suggests otherwise.  Passive transfer of anti MPO in mice induced ANCA associated necrotizing crescentic GN with activation of alternate complement system.  The researcher highlighted the role of C5a receptor in the mediation of this disease. As we know, C5 has a role more downstream close to the MAC system in the complement cascade.  Hence blocking C5a receptor will halt alternate pathway.  The researchers then showed that C5a receptor/CD88 engagement enhances the inflammation and C5L2 ( C5 a like receptor) suppresses inflammation.  Given an oral agent that blocks C5a receptor/CD88 ameliorated the GN in the mouse model. No human trials have been suggested yet but pharmaceuticals are already on the go for this proof of concept.
          In a different study, the elevated plasma and urinary C5a levels indicated complement activation in human ANCA disease. CD88 expression was downregulated, and C5L2 was upregulated in ANCA-associated glomerulonephritis.

          The role of complement in ANCA disease is not completely novel. If C5A receptor can be of help, why not block C5 directly with an agent we already have for C3GN, DDD, PNH and aHUS: eculizumab.
Looking at clinicaltrials.gov, we find a withdrawn study.( thanks to anonymous for pointing this out)

Tuesday, December 11, 2012

ANCAs and Alpha-1 antitrypsin- any link?


Alpha 1- antitrypsin (AAT) is a major inhibitor of proteinase 3.  In one with AAT deficiency, it has been postulated that there may be an increase in proteinase 3 activity due to inability of AAT to inactivate the proteinase 3.  This imbalance may lead to ANCA vasculitis.  See below for some interesting aspects of this association. One study looked at an association of the allele of AAT deficiency and relation to ANCA disease. While a cause and effect cannot be proven, this is an interesting association. As early as 1993, this assocaition was encountered and studied. Interestingly, another study that looked at AAT inhibitor phenotypes and levels examined in 40 ANCA positive cases of systemic vasculitis, an excess of PiZ and PiS alleles were associated with the development of pulmonary haemorrhage and alpha-1-proteinase inhibitor levels were lower in the subgroup with pulmonary haemorrhage. However, this allelic imbalance and reduced alpha-1-proteinase inhibitor level was not confined to antiproteinase 3 positive patients and did not appear to be associated with other organ involvement or disease severity.

Post by

-Mala Sachdeva, MD



Thursday, May 31, 2012

KDIGO Glomerular Disease Guidelines: ANCA vasculitis


Pauci immune focal and segmental necrotizing GN guidelines by KDIGO


1. Initial treatment( cyclophosphamide and steroids) ( Grade 1A)
2. Rituximab and steroisd be used as alternative when above is contraindicated ( Grade 1B)
3. Plasmapheresis be added if there is rapid rise in crt or on dialysis (Grade 1C)
4. Plasmapheresis be added for pulmonary hemorrhage( Grade 2C)
5. Overlap diseases of ANCA and anti GBM - use plasmapheresis (Grade 2D).
6. If dialysis dependent for 3 months, stop cyclophosphamide if no extra renal manifestations( Grade 2C).
7. Maintenance therapy should be used if achieved remission ( Grade 1B)
8. Continue maintenance therapy for 18 months who achieved remission ( Grade 2D).
9. No maintenance in dialysis dependence and no extra renal manifestations ( Grade 1C)
10. Azathioprine is first choice at 1-2mg/kg/day orally as maintenance therapy ( Grade 1B)
11. MMF up to 1mg BID if above not possible( Grade 2C)
12. Bactrim use as adjunct( Grade 2B)
13. Methotrexate for maintenance  if intolerant to azathioprine and MMF if GFR >60 ( Grade 1C)
14. Etanercept should not be used as adjunct therapy ( Grade 1A).
15. Severe Relapse should be treated just like initial disease ( Grade 1C)
16. Other relapses should mean to re starting maintenance therapy ( Grade 2C)
17. Resistant disease:- Rituximab should be used ( 1C), IVIG( 2C) and plasmapheresis (2D)
18. ANCA titer alone should not change therapy ( Grade 2D)
19. Delaying transplantation till complete extrarenal manifestations have been in remission for 12 months( Grade 1C)
20. Not delaying transplantation for those in complete remission but still ANCA positive( Grade 1C).

For full details: http://www.nature.com/kisup/journal/v2/n2/pdf/kisup201226a.pdf
Image source: UNC kidney center website

Wednesday, March 7, 2012

IN THE NEWS: FSP-1



 Urinary FSP1 as a possible acute glomerulonephritis biomarker.  Apparently when you have renal injury, it leads to accumulation of fibroblast specific protein 1 (FSP-1) in the kidney and this could serve as a biomarker. A paper in JASN showed that this urinary FSP-1 was elevated significantly more in crescentic GN and later even became undetectable after treatment.  The authors suggest that it could be screening test for active GN.  Interestingly, the same group had found this elevation in diabetic nephropathy as well,  Take a look at the original paper in JASN.  Is it really? or is it a marker of podocyte damage. Take a look at similar paper now using FSGS showing that it might reflect detachment of foot processes. The same authors have shown that this entity is EMT in tubular interstitial fibrosis.  And HIVAN as well.  Is FSP1 measurement as measuring podocyturia? Or are we truly getting to a potential urinary marker?


Wednesday, January 18, 2012

IN THE NEWS: Soluble FLT-1 and ANCA... Not just pre eclampsia!

A recent study published in the Feb JASN 2012 issue showed that there is an elevated soluble FLT-1 that is inhibiting the endothelial repair of PR3 ANCA vasculitis.  This is very interesting as sFLT-1 now is not just associated with pre eclampsia.  Vasculitis causes endothelial damage. VEGF is a factor that leads to endothelial repair. The authors show that in the PR3 ANCA vasculitis state, the VEGF factors are inhibited by sFLT-1 and leads to decreased endothelial repair and hence worse vasculitis.
sFLT1 are elevated in placental vascular dysfunction and pre eclampsia. sFLT1 is produced by placental cytotrophoblasts but also monocytes and endothelial cells and it inhibits VEGF.  This study is interesting as it showed that sFLT1 was elevated in patients with PR3 ANCA vasculitis and this was due to monocyte activation activating the alternate complement components. They were increased in anti GBM and anti MPO disease but not significantly as in patients with anti PR3 related disease when compared to controls in their experiment. Interestingly, postulated that anti sFLT1 agents might be useful.

Take a look at the full reference
http://www.ncbi.nlm.nih.gov/pubmed/22034638

Tuesday, January 17, 2012

ANAGRAMS: Secondary causes of ANCA disease

Check out a fun way to learn Nephrology using anagrams on secondary causes of ANCA disease.
Test your knowledge at eAJKD.

Friday, January 13, 2012

TOPIC DISCUSSION: Atypical ANCA and it's significance?


Three types of positive ANCA are reported: C-ANCA, P-ANCA and atypical ANCA, based on the staining pattern of the neutrophils in the immunofluorescence assay.

C-ANCA: A coarse, clumpy, granular cytoplamic staining of neutrophils, which is usually associated with anti PR3 antibodies
P-ANCA:  A perinuclear staining pattern of neutrophils which is usually associated with anti MPO antibodies. The presence of some anti-nuclear antibodies (homogeneous ANA) may interfere with ANCA testing and invalidate the reporting of P-ANCA. In this situation, an indeterminant result is reported.  However, ANA do not usually interfere with ELISA testing.
Atypical ANCA: Patterns of neutrophil cytoplasmic and / or perinuclear fluorescence  other than the two above, which  occurs when neutrophil antigens other than MPO or PR3 are the antibody target.
Confusion arises when p-ANCA and c-ANCA are negative and so is MPO and PR3 but then you get an atypical ANCA positive. The indirect immunoflourescence (IIF) is the above test used and is not that good as the ELISA.   When the IIF and ELISA are used,  here is a specific things can arise:

1. C-ANCA positive:- suggestive of Wegener's Granulamatosis(WG), Microscopic polyangitis( MPA) or Churg Strauss(CS) - usually ELISA with MPO and PR3 is then performed to confirm
2. P-ANCA positive:- suggestive of MPA, and some times WG and CS. Again ELISA is needed.
3. Atypical ANCA positive:- Not associated with WG, MPA or CS.  Usually seen with chronic inflammation, bowel diseases and other autoimmune diseases. ELISA still needed to make sure no MPO or PR3 positivity is noted
4. ANCA negative:- Treated or inactive WG, MPA or CS. 
5. ANA positive, P-ANCA positive, C-ANCA negative:- Can be secondary due to +ANA. Again MPO and PR3 are needed
6. PR3 negative, MPO negative, +atypical ANCA:- Could be chronic infections, inflammatory bowel diseases, or autoimmune diseases ( usually not ANCA disease)
7. C-ANCA Positive, PR3- ++:- Active WG or MPA or CS
8. C-ANCA Positive, MPO ++:-Active MPA and sometimes CS or WG
9. Atypical ANCA +, PR3 +, MPO +:- Inflammatory bowel disease, doesn't occur in WG or MPA or CS
10. Atypical ANCA+, MPO+++:- Usually not seen except perhaps drug induced vasculitis

Take a look at this special article to get a more complete review of this specific testing.

Monday, September 26, 2011

IN the NEWS: HB -EGF and RPGN


Any research in RPGN and glomerular diseases that can possibly lead to any new drug development are good to review. A recent study in Nature Medicine diseases the role of the heparin binding epidermal growth factor like growth factor in the role of glomerular disease. The researchers in this paper showed denovo induction of heparin-binding epidermal growth factor–like growth factor (HB-EGF) in intrinsic glomerular epithelial cells (podocytes) from both mice and humans with RPGN. HB-EGF induction increases phosphorylation of the epidermal growth factor receptor (EGFR) in mice with RPGN. In mice without the activation of HB-EGF and no EGFR receptor activation, course of RPGN is improved. Conditional deletion of the Egfr gene from podocytes of mice alleviated the severity of RPGN. Pharmacologic blockaded of the EGFR also can alleviate RPGN.  
When these receptors are taken out of the equation- the disease doesn't take full form. 
There are EGFR receptor antagonist that are being used. Not for RPGN but for cancers.

The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related the tyrosine kinases. Upregulation has led to colon, breast and neurological cancers.

There are many anticancer therapeutics directed against EGFR, including gefitinib and erlotinib for lung cancer, and cetuximab for colon cancer. Cetuximab is a monoclonal antibody inhibitor. This allows for tyrosine kinase inhibition as well leading to treating the cancer.
As we think these above agents might be beneficial for RPGN, we have to be careful as the first method is a tyrosine kinase inhibitor approach which can have renal side effects as pre eclampsia like syndromes, hypertension and thrombotic microangiopathies. 
This is where Oncology and Nephrology are at the forefront of sharing information. Congrats on a nicely designed study.

Ref:
http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2491.html
Image source: http://www.mc.vanderbilt.edu/lens/article/?id=204

Tuesday, May 3, 2011

CLINICAL CASE 36, ANSWERS AND SUMMARY

Which of the following regarding Anti GBM disease in elderly is true?

This entity is non existent in the age> 65   0%
Anti GBM disease in the elderly is more of a female predominance
15% 
Anti GBM disease in the elderly is more severe than in the younger patients
17%
Anti GBM disease has more severe lung hemorrhage than younger patients
10%
Anti GBM disease has a significantly higher proportion of positive ANCA results in this age group
57%

Good work all. Majority got this one right. Recently in AJKD this topic was reviewed looking especially at cases in the elderly.  This entity does exist in the elderly and fairly common. It has more of a male predominance and it is actually LESS severe than when it happens in younger patients.  The lung disease is also LESS severe. The correct answer hence is the last one- it does occur a lot of time concurrently with a positive ANCA blood test in this age group. This group also has lower proteinuria at presentation and higher GFR on presentation. 

Ref:

All Posts

Search This Blog